Cote d'Ivoire vs Singapore: Access to anti-retroviral drugs, female (%)
Cote d'Ivoire
84.0%
in 2024
Singapore
84.0%
in 2023
Cote d'Ivoire rank
50th
Singapore rank
50th
Access to anti-retroviral drugs, female (%) over time
- Cote d'Ivoire
- Singapore
How they compare
Cote d'Ivoire currently reports 84.0% against 84.0% in Singapore, a difference of 0.0%.
Across all 24 years both countries report, Singapore has been ahead every year.
Cote d'Ivoire ranks 50th and Singapore ranks 50th of 141 countries.
Singapore has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cote d'Ivoire | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.8% | 19.9% | 15.1% | Singapore |
| 2010s | 41.6% | 59.6% | 18.0% | Singapore |
| 2020s | 76.8% | 80.8% | 4.0% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Cote d'Ivoire or Singapore?
- Cote d'Ivoire, at 84.0% against 84.0% in Singapore as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Cote d'Ivoire and Singapore?
- 0.0%, with Cote d'Ivoire ahead.
- How many years of comparable data are there for Cote d'Ivoire and Singapore?
- 24 years are reported by both, from 2000 to 2023.
- How do Cote d'Ivoire and Singapore rank globally for access to anti-retroviral drugs, female?
- Cote d'Ivoire ranks 50th and Singapore ranks 50th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.